

## **Coronavirus SARS-CoV-2: Analysis of subgenomic mRNA transcription, 3CLpro and PL2pro protease cleavage sites and protein synthesis**

Corresponding autor: Miguel Ramos-Pascual

### **Abstract**

Coronaviruses have recently caused world-wide severe outbreaks: SARS (Severe Acute Respiratory Syndrome) in 2002 and MERS (Middle-East Respiratory Syndrome) in 2012. At the end of 2019, a new coronavirus outbreak appeared in Wuhan (China) seafood market as the first focus of infection, becoming a pandemic in 2020, spreading mainly into Europe and Asia [Zu et al 2020]. Although the virus family is well-known and symptoms are similar to other coronaviruses (fever, pneumonia, small pleural effusions), this specific virus type presents considerable differences, as higher transmission and mortality rates, being a challenge for diagnostic methods, treatments and vaccines.

Coronavirus.pro (SARS-CoV-2) App is a module of Virus.pro, a C++ application which simulates Coronavirus replication cycle. This software identifies virus types in short times and provides FASTA files of virus proteins, a list of RNA sequences (regulatory, packaging, transcription and translation) and secondary structures (stem-loops, helices, palindromes, mirrors), once the virus genome has been sequenced. The code is supported by other bio-informatics tools, such as Vienna RNA package, Varna software and ClustalW2.

Coronavirus.pro has identified 2019-nCoV virus as a beta-coronavirus more close related to SARS type than to MERS. However, it presents significant differences, such as the spike glycoprotein precursor, characteristic of this virus type, and the increased number of transcription regulating sequences (TRS), producing more subgenomic mRNAs and synthesizing more fusion proteins than SARS/MERS. This could be related with those severe health effects (toxicity) on host patients than other coronaviruses.

The software has identified a list of structural, non-structural and accessory proteins in 2019-nCoV virus genome similar to SARS and MERS. It has found also several ORF encoding some accessory proteins with unknown TRS (i.e. AP3b, AP9b, AP11, AP12 and AP14a/b). Furthermore, there is a subgenomic mRNA, the shortest with 374bp, which translates no proteins, specific only of SARS type virus. Finally, there are some accessory proteins AP2 in SARS/MERS and AP2a/b in 2019-nCoV, encoded before ORF1.2 and ORF1.4 respectively, which have not been previously reported.

2019-nCoV protein sequences have been compared with those from SARS and MERS. As 3CLpro (nsp5) and RdRp (nsp12) have >90% similarities with SARS, some antiviral drugs effective with SARS coronavirus, such as protease inhibitors or RNA-dependent RNA polymerase inhibitors could be also effective to this virus type. Nevertheless, further comparisons would be required, including other types of estimators.

These results are useful as a first step with other bio-informatics and pharmacological tools in order to develop diagnostic methods (real time RT-PCR or ELISA tests), new vaccines or antiviral drugs, which avoid virus replication in any stage: fusion inhibitors, RdRp inhibitors and PL2pro/3CLpro protease inhibitors.

Keywords: SARS-CoV, MERS-CoV, 2019-nCoV, Coronavirus, virus proteins, protease cleavage sites

## 1. Introduction

Coronaviruses (CoVs) are specific viruses that cause diseases in mammals and birds, including humans, with symptoms such as enteritis in bats, mice and pigs and upper respiratory malfunctions and potentially lethal respiratory infections in humans [Fehr and Perlman 2015]. A large variety of coronaviruses have been previously studied and analyzed. These viruses are responsible in a 2-10% of common cold in immunocompetent individuals (i.e. 229E, OC43E, NL63 and HKU1 types). However, other types can cause severe respiratory syndromes, such as SARS-CoV (Severe Acute Respiratory Syndrome Coronavirus) that caused an epidemic in 2002-2003, with origin in Guangdong (China) [Vijayanand et al 2004] and MERS-CoV (Middle Eastern Respiratory Syndrome Coronavirus) expanded in 2014-2015 through Saudi Arabia into Egypt, Oman and Qatar, from bats to dromedary camels, as the source of infection in humans [Aleanizy et al 2017].

At the end of 2019, a new SARS outbreak appeared in Wuhan (China) seafood market as the first focus of infection, becoming a pandemic in 2020 and spreading mainly into Europe and Asia, declaring general state of alarm in several countries, as Spain and Italy [Liao et al 2020, Zu et al 2020, Giovanetti et al 2020].

Coronavirus infections have normally low case fatality rates, with symptoms more severe than common cold, affecting mainly respiratory tract (cilia epithelium of the trachea, nasal mucosa and alveolar cells of the lung). Although the virus family is well-known and symptoms are similar to other coronavirus (fever, pneumonia, small pleural effusions), this specific type of virus presents considerable differences, as a higher infection/transmission and mortality rate, being a challenge for disease protection, prevention, diagnostic methods, vaccines and treatments [Wu et al 2020, Zhu et al 2020].

Virus pharmacology is based on preventive actions (vector-based or RBD-based vaccines), diagnostic methods (real time RT-PCR or ELISA tests) and antiviral drugs. SARS-CoV and MERS-CoV epidemics have expanded the use of several drugs, specially virus cycle inhibitors against coronaviruses (fusion inhibitors, RdRp inhibitors or PL2pro/3CLpro protease inhibitors) [Li G and De Clercq 2019, Raoult et al 2020]

In order to develop these methods, virus replication cycle must be simulated through computerized tools, specially for this virus family, with a complex replication cycle. Coronaviruses synthesize in a first stage a viral RNA-dependent RNA polymerase (RdRp) and multiple proteases, transcribes several subgenomic mRNAs and translates them progressively into viral proteins through several ribosomal pathways: (-1) programmed frameshift, leaky scanning and internal ribosome entry site (IRES) [Plant et al 2005]. Some mRNAs include genes encoding large polypeptide chains, which are cleaved through 3CLpro and PL2pro proteases, producing non-structural proteins as enzymes for catalyzing assembly and packaging of new viruses [Sawicki et al 2007, Fehr and Perlman 2015, Oxford et al. 2016]

Coronavirus.pro (2019-nCoV) App is a C++ code which simulates Coronavirus replication cycle. This software identifies virus types in short times and provides FASTA files of virus proteins, a list of RNA sequences (regulatory, packaging, transcription and translation) and secondary structures (stem-loops, helices, palindromes, mirrors), once the virus genome has been sequenced [Ramos-Pascual 2019]. The code is supported by other RNA analysis tools, such as Vienna RNA package and Varna software [Gruver et al 2008, Darty et al 2009]. These results are useful as a first step with other bioinformatics and pharmacological tools in order to develop diagnostic methods, new vaccines and antiviral drugs.

## 2. The Coronavirus: classification, structure, genome and virus cycle

### 2.1 Classification

Coronaviruses (CoVs) are part of the order Nidovirales, from the family Coronaviridae and formed by several subtypes: Alpha-, beta-, gamma- and delta-coronavirus. Virus 229E and OC43, the first of being isolated and responsible of common cold, belong to alpha-coronavirus group I, while SARS and MERS are beta-coronavirus.

### 2.2 Structure of the virion

Coronaviruses have diameters from 100 to 160 nm with very large heavily glycosylated spikes (S) of 200kDa and 20 nm, placed around virus membrane as a crown, hence their name, in a trimer configuration (fig. 1).

Viral RNA genome is encapsulated in a helicoidal nucleocapsid phosphoprotein (N), known also as ribonucleoprotein (RNP), and enveloped into a virus particle with different membrane (M) and envelope glycoproteins (E).

Some coronaviruses include also a hemagglutinin-acetylase glycoprotein (HE) in the outer membrane. HEs helps during attachment, destroying certain sialic acid receptors in host-cell surface. Not all strains demonstrated hemagglutination, as observed only in beta-coronaviruses subgroup 2a (HCoV-HKU1, MHV) and toroviruses (BToV) [Brian et al. 1995, de Groot 2006]




Fig. 1 - Structure of a general Coronavirus virion particle

### 2.3 Virus genome

Coronavirus genome is a type of positive single-stranded RNA of approximately 30kb, the largest of RNA viruses, 5' capped, 3' polyadenylated and infectious. This Poly(A) tail allows coronaviruses direct translation after infection without needing an intermediate transcription stage.

Transcription initiation is regulated in coronaviruses by several types of consensus transcription regulating sequences: TRS1-L, 5'-cuaaac-3', TRS2-L, 5'-acgaac-3' and merged into TRS3-L, 5'-cuaaacgaac-3'. These multiple TRS give place to several subgenomic polycistronic mRNAs, encoding structural, non-structural and accessory proteins. In case of some coronaviruses (i.e. MERS-CoV), transcription starts mainly in TRS2-L, while other coronaviruses start transcription indistinctly in all TRS, in a way of regulating protein frequencies [Sethna et al 1989, Irigoyen et al 2016].

Coronavirus genome includes multiple open-reading frames (ORF) containing genes which are transcribed by several transcription regulating sequences (TRS). Genes encoding non-structural proteins are placed at

5' UTR (ORF1.1, ORF1.2 ...), whereas at 3' UTR are genes for structural (N, M, E and S). These genes are interspaced with several accessory genes, encoding accessory proteins (AP), characteristics in number of each virus type. Some of these AP are not essential for in vitro or in vivo replication.

As transcription starts at different TRS in each subgenomic mRNA, the number of ORF genes is variable on virus type, and therefore the number of polypeptide chains. This produces different frequencies of non-structural proteins during virus cycle. For example, SARS produces ORF1.1 and ORF1.2 genes, whereas 2019-nCoV, produces ORF1.1 to ORF1.6 genes, synthesizing several groups of fusion proteins [van Boheemen et al. 2012]. A (-1) programmed slippery ribosome frameshift is placed approximately in the middle of ORF1 genes, then translated into polypeptides pp1a and pp1ab [Dinman 2012, Bock et al 2019]. Furthermore, Coronaviruses uses a leaky scanning mechanism (shunting) to synthesize proteins from overlapping ORF, translating different proteins from the same mRNA [Nakagawa et 2016].

Surface glycosylated Spike (S) is processed in some coronaviruses from a proteolytic cleavage of a spike precursor [Belouzard et al 2009]. The number of spike precursors is characteristic of each coronavirus. For example, in the case of SARS-CoV, two spike precursors (Sp1 and Sp2) are proteolytically cleaved, producing two surface glycosylated spikes (S1 and S2) and a protease fragment (S0).

Figure 2 shows a scheme of the main genes in Coronavirus family, including ORF1.1 with a -1 slippery ribosome frameshift. Genes transcribed from different TRS are placed in another line. Figure 3 presents a scheme of ORF1.1 gene and non-structural proteins (nsp1 to nsp16), including accessory protein AP2. Tables 1 and 2 summarize main genes and proteins of SARS-CoV and MERS-CoV coronaviruses.




Fig. 2 – Scheme of the genes in viral genomes from Coronavirus family: non-structural proteins (white), structural (green), accessory (blue) and other ORF (grey). Fusion proteins and subgenomic mRNAs are not depicted.




Fig. 3 – Scheme of the ORF1.1 gene and description of the non-structural proteins (nsp1 to nsp16) of SARS-CoV (SWISS Model) Accessory protein AP2 has been included

Table 1 - Summary of the main genes and characteristics of SARS-CoV [Xu et al 2003, Liu et al 2014] and MERS-CoV [Li et al 2019]

Type	Coding Genes	Protein	Description
Non-structural	ORF 1.1	pp1a	Polyprotein 1a
		pp1ab	Polyprotein 1ab, [-1] PRF
Structural and accessory ORF	ORF 1.2	AP2	Accessory protein AP2, unknown
		pp1a	Polyprotein 1a
		pp1ab	Polyprotein 1ab, [-1] PRF
	ORF2	Sp <sup>(a)</sup>	Surface Glycosylated Spike precursor (Sp)
		S	Surface Glycosylated Spike (S)
		S0	Spike protease fragment (S0)
	ORF3a	AP3a	Viral pathogenesis, apoptosis induction, cell cycle arrest, modulation of NF-kb-mediated inflammation
	ORF3b	AP3b <sup>(b)</sup>	IRES translation, viral pathogenesis, not required for SARS-CoV replication
	ORF4	E	Envelope membrane
	ORF5	M	Transmembrane glycoprotein
		AP5	Unknown, only MERS
	ORF6	AP6	Type I IFN production and signaling inhibition, only SARS
	ORF7	AP7a/b	Viral pathogenesis, apoptosis induction, cell cycle arrest, modulation of NF-kb-mediated inflammation
	ORF8	AP8a/b <sup>(b)</sup>	
	ORF9	N	Nucleocapsid phosphoprotein
ORF9b	AP9b <sup>(b)</sup>	Viral pathogenesis, apoptosis induction, cell cycle arrest, modulation of NF-kb-mediated inflammation, named AP8b in MERS	
ORF11	AP11 <sup>(b)</sup>	Unknown, only SARS	
ORF14	AP14a/b <sup>(b)</sup>	unknown	

(a) - Spike precursors length and number depends on virus type (Sp=S+S0) (b) TRS unknown

Table 2 - Description of non-structural proteins (Polyprotein pp1ab) of SARS and MERS coronavirus [Chen et al 2020]

Protease	Protein	Comments
PL2pro	nsp1	Leader protein, suppress antiviral host response, promotes degradation of host mRNAs, inhibiting IFN signaling
	nsp2	unknown
	nsp3	ADP-ribose 1-phosphatase, PL2pro (papain-like protease 2)
	nsp3a	unknown
	nsp3b	unknown
3CLpro	nsp4	DMV formation, complex with nsp3
	nsp5	3C-like (3CLpro), Mpro, polypeptides cleaving
	nsp6	Restricting autophagosome expansion, DMV formation
	nsp7	Cofactor with nsp8 and nsp12
	nsp8a	DNA primase, cofactor with nsp7 and nsp12
	nsp8b	
	nsp9	Dimerization and RNA/DNA binding activity
	nsp10	interacts with nsp14 and nsp16 [Bouvet et al 2010,2012]
	nsp11	Short peptide at pp1a end
	nsp12	RNA-dependent RNA polymerase (RdRp)
	nsp13a	Helicase, NTPase nucleoside 5' triphosphatase (ZD, NTPase/HEL)
nsp13b		
nsp14	3'-to-5' exoribonuclease (nuclease ExoN homolog)	
nsp15	Endoribonuclease (endoRNase), evasion of dsRNA sensors	
nsp16	S-adenosylmethionine-dependent ribose 2'-O- methyltransferase (2'-O-MT)	

## 2.4 Virus replication cycle

As other viruses, Coronavirus employs glycosylated spikes placed in the outer surface to attach specific receptors of host cells (i.e. APN/ACE2/DPP4 receptor). Specially, betacoronaviruses attach to angiotensin-converting enzyme 2 (ACE2) receptor, a membrane protein expressed mainly in the surface of epithelial cells of the pulmonary alveolus [Jia et al 2005]. Once attachment is carried out, viral transmembrane is fused through an endocytotic pathway and viral RNA is released into the cell cytoplasm [Wang et al 2008]. Viral RNA genome is positive stranded, 5' capped and 3' polyadenylated, therefore it can be directly translated into proteins by host-cell ribosomes. Specifically, ORF1 gene contains several non-structural proteins in a polypeptide complex, that once translated, is catalytically autoprocessed by 3CL/2PL proteases, and assembled into a replicase-transcriptase complex with RNA-dependent RNA activity (RdRp). At this point, several subgenomic mRNAs are produced by transcription and translated into structural (N, M, E and S), non-structural and accessory proteins (AP), assembling new virions. These virus particles are formed on smooth-walled vesicles located between the ER and the Golgi, named as ERGIC (Endoplasmic Reticulum Golgi Intermediate Compartment). Once these vesicles fuse with the plasma outer membrane, virions are released to continue infection (see fig 4).




Figure 4 – Scheme of a Coronavirus cycle replication: [1] Attachment and fusion (APN/ACE2/DPP4), [2] endocytosis, [3] translation of vRNA (ORF1.1), [4] assembly of RNA-dependent RNA polymerase (RdRp) and other non-structural proteins (nsp) by proteases, [5] transcription of subgenomic mRNAs by RdRp, [6] translation of subgenomic mRNAs and protein synthesis, [7] assembly into membraneous regions ERGIC and [7] fusion with plasma membrane and exit (BioRender <http://app.biorender.io>)

### 3. Coronavirus.pro

#### 3.1 Description

Coronavirus.pro is a module of Virus.pro, a C++ software application developed in modules that simulate mainly RNA and DNA virus replication cycles: Ebola, HIV-1, HCV (Hepatitis C), CoV, HSV1 (Human Herpes Virus), PV1 (Poliovirus 1, Mahoney) The software reproduces several virus cycle replication stages, from attachment and fusion to virion exit from host-cell, focusing into more complex stages, such as subgenomic mRNAs translation, protein synthesis and protease catalytic processing (see fig. 5 and 6).

Virus.pro contains a set of RNA/DNA databases and protein databases to scan viral genome and protein sequences for recognized motifs, reconstruct secondary structures (helices, stem-loops, palindromes, mirrors) and identify RNA-protein interaction regions. The software is supported with other applications, as Vienna RNA package, for bracket-dot notation and Varna for plotting (see fig. 7) [Gruber et al 2008, Darty et al 2009]. The code contains also machine-learning algorithms, in which new virus, RNA/DNA sequences and proteins can be included to the internal databases to future identifications and analysis. The software has been validated with other bio-informatic tools, as Blastp or Swiss-Model [Altschul et al 1990, Camacho et al 2008, Waterhouse et al 2018, Ramos-Pascual 2019].

```
=====  
Virus.pro  
=====  
Analysis of virus cycle replication:  
  
    [1] CoV (SARS, MERS)  
    [2] Ebola  
    [3] HIV-1  
    [4] HCV (Hepatitis C virus)  
    [5] HSV1 (Human Herpes Simplex virus 1)  
    [6] PV1 (Poliovirus 1, Mahoney)  
    [7] Other viruses  
  
Analysis of RNA/DNA or protein sequences:  
  
    [8] Sequence analysis  
  
RNA / protein interactions:  
  
    [9] RNA-protein interaction  
    [10] RNA-RNA interaction  
    [11] Protein-protein interaction  
=====
```

Fig. 5 – Software Virus.pro for simulating RNA/DNA virus replication cycles

```
=====  
CoronaVirus.pro - SARS/MERS/2019-nCoV Replication Cycle Simulation  
=====  
  
(1) Attachment and fusion (APN/ACE2/DPP4 receptor)  
(2) Endocytosis  
(3) Translation of vRNA (ORF1.1)  
(4) Assembly of RNA-dependent RNA polymerase (RdRp) and  
    other non-structural proteins (nsp) by proteases  
(5) Transcription of subgenomic mRNAs by RdRp  
(6) Translation of subgenomic mRNAs and protein synthesis  
(7) Assembly into membraneous regions ERGIC  
(8) Fusion with plasma membrane and exit  
=====
```

Fig. 6 – Software Coronavirus.pro for simulating SARS/MERS/2019-nCoV virus replication cycle






Fig. 7 - Scheme of the Virus.pro software (RNA module)

Coronavirus.pro includes a preprocessor to convert viral genome sequence file into a plain sequence format (nucleotides list). Preprocessor supports genomes in formats: FASTA, EMBL, GenBank, Stockholm 1.0 and GCG (see fig 8).

```

=====
! Software for pre-process virus genome file into plain sequence format (nucleotides):
! (RNA/DNA virus genome is saved with output name: file00.tmp)
! - Enter filename with extension (i.e. hsv.fasta)
! - Select filetype: (a) FASTA (b) EMBL (c) GenBank (d) Stockholm 1.0 (e) GCG (f) Others
=====

```

Fig. 8 – Software for preprocessing viral genome sequence file. Supported formats: FASTA, EMBL, GenBank, Stockholm 1.0 and GCG

### 3.2 Simulation of translation, protein synthesis and protease cleavage sites

Each subgenomic mRNA transcribed by coronavirus RNA-dependent RNA polymerase (RdRp) is translated into virus proteins by host-cell ribosomes. ORF1.1 and ORF1.2 in SARS-CoV, ORF1.1 to ORF1.4 in MERS-CoV and ORF1.1 to ORF1.6 in 2019-nCoV encode a polypeptide chain of variable length, with a -1 programmed ribosomal frameshift (PRF). This frameshift is followed by a pseudoknot structure located few nucleotides downstream and is able to change reading frame -1 position backward, translating an alternative polypeptide (pp1ab with frameshift). Frameshifting probability is approximately between 5-10%. In some cases, translation starts after a leaky scanning (shunting) [Dinman 2012, Bock et al 2019] or Internal Ribosomal Entry Site (IRES) [Bonnal et al 2003, Mokrejs et al 2006]

After this, viral proteases cleave with enzymatic activity these polypeptides at specific cleavage sites to synthesize non-structural proteins [Kierner et al 2004]. Protease cleavage sites are predicted depending on protease family (aspartic, cysteine, metallo or serine protease) and through specific cleavage patterns [Song et al. 2012] Coronavirus proteases are a papain-like (PL2<sup>pro</sup>) and a cysteine 3C-like proteinase (3CL<sup>pro</sup>) synthesized from nsp3 and nsp5, respectively [Chen et al 2005].

Coronavirus.pro simulates proteolytic effect of coronavirus proteases PL2pro and 3CLpro through multiple protease pattern sequences (table 3). Most of these sequences have been previously validated in some research studies and others have been proposed by comparison with protein databases, as UniProt or NCBI, and recursive simulations with the software [Kierner et al 2004, Sulea et al 2006, Ramos-Pascual 2019].

Table 3 - Protease cleavage site sequences for Coronavirus proteins (SARS -CoV and MERS-CoV)

PCS	Sequence	SARS-CoV	MERS-CoV
[1.1]	VSQIQ↓SRLT	S1/S2-S0	-
[1.2]	GKIQD↓SLSST	S1/S2-S0	-
[1.3]	GAMQT↓GFTTT	-	S1/S2-S0
[2]	YPKLQ↓ASQAW	M1-M2	-
[3]	SNNLQ↓GLEN	-	N1-N2
[4]	ETRVQ↓CSTN	-	N2-N3
[5]	ELNGG↓AVTRY	nsp1-nsp2	-
[6]	DPKGG↓YAQNL	-	nsp1-nsp2
[7]	RLKGG↓APIKG	nsp2-nsp3	nsp2-nsp3
[8]	KSSVQ↓SVAG	nsp3-nsp3a	-
[9]	KNTVK↓SVGKF	nsp3-nsp3a	-
[10]	AQGLK↓KFYKE	-	nsp3-nsp3a
[11/4]	ETRVQ↓CSTN	nsp3a-nsp3b	nsp3a-nsp3b
[12]	SLKGG↓KIVST	nsp3b-nsp4	-
[13]	KIVGG↓APTWF	-	nsp3b-nsp4
[14]	SAVLQ↓SGFRK	nsp4-nsp5	nsp4-nsp5
[15]	GVTFQ↓GKFK	nsp5-nsp6	-
[16]	GVVMQ↓SGVRK	-	nsp5-nsp6
[17]	VATVQ↓SKMSD	nsp6-nsp7	-
[18]	VATLQ↓AENV	nsp7-nsp8a	-
[19]	VAAMQ↓SKLTD	nsp8a-nsp8b	nsp6-nsp7
[20]	HSVLR↓APMST	-	nsp7-nsp8a
[21]	AVKLQ↓NNELS	nsp8b-nsp9	nsp8a-nsp9
[22]	TVRLQ↓AGNAT	nsp9-nsp10	nsp9-nsp10
[23]	EPLMQ↓SADA	nsp10-nsp11/nsp12	-
[24]	ALPQS↓KDSNF	-	nsp10-nsp11/nsp12
[25]	HTVLQ↓AVGAC	nsp12-nsp13a	nsp12-nsp13a
[26/18]	VATLQ↓AENV	nsp13a-nsp14	nsp13a-nsp13b
[27]	YKLQS↓QIVTG	-	nsp13b-nsp14
[28]	FTRLQ↓SLENV	nsp14-nsp15	-
[29]	TKVQG↓LENIA	-	nsp14-nsp15
[30/2]	YPKLQ↓ASQAW	nsp15-nsp16	nsp15-nsp16

Cleavage sites are identified with a coarse approximation in which each protease cleavage sequence (A) scans through each protein aminoacid sequence (B). If  $k_a$  and  $k_b$  are respectively the amino acid length of A sequence and protein B, protein is cleaved at positions with the highest Levenshtein distance, calculated as:

for (i = 1; i <=  $k_a$ ; i++) d[i][0] = i; for (i = 1; i <=  $k_b$ ; i++) d[0][i] = i;

for (i = 1; i <=  $k_a$ ; i++)

for (j = 1; j <=  $k_b$ ; j++)

c = 0;

if (a[i - 1] == b[j - 1]) { c = 0; }

else { c = 1; };

d[i][j] = min(d[i - 1][j] + 1, d[i][j - 1] + 1, d[i - 1][j - 1] + c)

}

}

## 4. Results and discussion

### 4.1 Virus identification: comparison with SARS-CoV and MERS-CoV

Coronavirus.pro has been used with sequence MN908947 (Wuhan seafood market pneumonia virus isolate Wuhan-Hu-1, complete genome) This sequence is specific of the virus type that caused the outbreak in Wuhan of Hubei province (China), the first infection focus (23-jan-2020), which has been named as 2019-nCoV [NCBI database]

The code has been also applied to other coronavirus types, such as sequences NC004718 (SARS coronavirus, complete genome) and NC019843 (MERS Middle East respiratory syndrome coronavirus, complete genome) [Snijder et al 2003, Moreno et al 2017], which have been taken as reference sequences. Other sequences have been also applied to compare similarity with 2019-nCoV virus genome (see table 4)

Table 4 - Summary of Coronavirus sequence files applied to Coronavirus.pro software

Virus	Sequence	Date	Description	bp	Comments
2019-nCoV	MN908947	23-JAN-2020	Wuhan seafood market pneumonia virus isolate Wuhan-Hu-1 (2019-nCoV)	29903	[ref]
MERS-CoV	NC019843	13-AUG-2018	Middle East respiratory syndrome coronavirus	30119	[ref]
SARS-CoV	NC004718	13-AUG-2018	SARS-CoV coronavirus	29751	[ref]
	KY417149	18-DEC-2017	Bat SARS-like coronavirus isolate Rs4255	29743	-
	AY278488	01-SEP-2009	SARS coronavirus BJ01 isolate genome sequence	29725	-

### 4.2 Coronavirus RNA structure

#### 4.2.1 Regulatory regions: 5'utr

Beta-coronaviruses have several stem-loop structures in the 5'utr region (SL1 toSL5C). The first transcription regulating sequence (TRS-L) is placed around the same positions in all beta-coronaviruses (SL3).

MERS-CoV presents a 5'utr region of 356bp, with a TRS-L without SL3. Stem-loop SL4b is only present in 2019-nCoV and MERS-CoV. Furthermore, there are several regulatory sequences (RS) with unknown functionality. Stem-loops SL6 and SL7 are placed into the adjacent ORF1 coding region. [Yang and Leibowitz 2015, Madhugiri et al 2018]

SARS-CoV and 2019-nCoV have a common 5' utr region of approximately 300bp, with several negative regulatory elements: NRE-I (IL-2R/EBS), NRE-II (Ap1) and NRE-III (Ap1) at positions 101/153/250 and 104/154/251, respectively. Stem-loop SL4b is absent in SARS-CoV, whereas in 2019-nCoV contains a palindrome sequence (-UAAUUA//UAAUUA-) with an unknown function.

Figures 9 to 11 shows 5'utr regions in MERS-CoV, SARS-CoV and 2019-nCoV coronaviruses, obtained through bracket-dot notation from Vienna RNA package and plotted with Varna software.




Fig. 9 – MERS-CoV [1-356bp] - Scheme of the 5' utr secondary structures (SL1-SL5C)





Fig. 10 – SARS-CoV [1-300bp] - Scheme of the 5' utr secondary structures (SL1-SL5C)



## 2019-nCoV

Fig. 11 – 2019-nCoV [1-300bp] - Scheme of the 5' utr secondary structures (SL1-SL5C)

### 4.2.2 Regulatory regions: 3' utr

Beta-coronaviruses have a short 3'utr region of approximately 100bp with a stem-loop of variable length followed with a poly(A) tail. This stem-loop, in the case of MERS-CoV is 27bp, including other recognition sequences, different as SARS-CoV and 2019-nCoV coronaviruses, as presented in figure 12. The 3' utr region of these coronaviruses contains also a conserved pseudo-knot structure of approximately 55bp [Lin et al 1996, Yang and Leibowitz 2015, Peng et al 2016].

## SARS-CoV

## 2019-nCoV

## MERS-CoV




Fig. 12 – Scheme of the 3' utr secondary structures [1-100bp]: stem-loop (SL) and Poly(A) tail

### 4.3 Protease cleavage sites

Coronavirus.pro has predicted all canonical protease cleavage sites in coronavirus polypeptides, from nsp1 to nsp16. Furthermore, the software has identified a protease cleavage site in spike glycoprotein precursors (Sp) in all coronaviruses. This cleavage site splits spike precursors (Sp) into S/S0 proteins, where S0 is the same protease fragment in both precursors.

Another cleavage site has been predicted in membrane protein (M) of 2019-nCoV virus, producing fragments M1/M2. In the case of MERS-CoV nucleocapsid (N), the software has found two protease cleavage sites, N1/N2 and N2/N3. In addition to these cleavage sites, the code has identified other protease cleavage sites giving place to some hypothetical proteins, as nsp3a↓nsp3b, nsp8a↓nsp8b and nsp13a↓nsp13b (see table 5). These cleavage sites must be discussed in detail and supported with other methods.

Table 5 - Protease cleavage sequences predicted by Coronavirus.pro

	Protein		PCS	SARS-CoV	PCS	2019-nCoV	PCS	MERS-CoV
Structural proteins	S1 & S2	S0	[1.1]	SQIQE↓SLTTT	[1.2]	GKIQD↓SLSST	[1.3]	GAMQT↓GFTTT
	M1	M2	[2]	YKLGA↓SQRVG	[2]	YKLGA↓SQRVA	-	-
	N1	N2	-	-	-	-	[3]	NRLQA↓LESGK
	N2	N3	-	-	-	-	[4]	QRVQ↓SITQR
Non-structural proteins	nsp1	nsp2	[5]	ELNGG↓AVTRY	[5]	ELNGG↓AYTRY	[6]	DPKGG↓YAQNL
	nsp2	nsp3	[7]	RLKGG↓APIKG	[7]	LKGG↓PTKVT	[7]	RLKGG↓APVKK
	nsp3	nsp3a	[8]	NSVKS↓VAKLC	[9]	KNTVK↓SVGKF	[10]	AQGLK↓KFYKE
	nsp3a	nsp3b	[11/4]	TRVEC↓TTIVN	[11/4]	TRVEC↓TTIVN	[11/4]	TRVEA↓STVVC
	nsp3b	nsp4	[12]	SLKGG↓KIVST	[12]	ALKGG↓KIVNN	[13]	KIVGG↓APTWF
	nsp4	nsp5	[14]	SAVLQ↓SGFRK	[14]	SAVLQ↓SGFRK	[14]	GVLQS↓GLVKM
	nsp5	nsp6	[15]	GVTFQ↓GKFKK	[15]	VTFQS↓AVKRT	[16]	GVVMQ↓SGVRK
	nsp6	nsp7	[17]	VATVQ↓SKMSD	[17]	VATVQ↓SKMSD	[19]	VAAMQ↓SKLTD
	nsp7	nsp8a	[18]	ATLQA↓IASEF	[18]	ATLQA↓IASEF	[20]	SVLQA↓TLSEF
	nsp8a	nsp8b	[19]	AAMQR↓KLEKM	[19]	AAMQR↓KLEKM	[21]	AVKLQ↓NNEIK
	nsp8b	nsp9	[21]	AVKLQ↓NNELS	[21]	AVKLQ↓NNELS		
	nsp9	nsp10	[22]	TVRLQ↓AGNAT	[22]	TVRLQ↓AGNAT	[22]	TVRLQ↓AGSNT
	nsp10	nsp11 & nsp12	[23]	EPLMQ↓SADAS	[23]	PMLQS↓ADAQS	[24]	ALPQS↓KDSNF
	nsp12	nsp13a	[25]	HTVLQ↓AVGAC	[25]	HTVLQ↓AVGAC	[25]	TTLQA↓VGCSCV
	nsp13a	nsp13b	[26/18]	VATLQ↓AENVT	[26/18]	VATLQ↓AENVT	[26/18]	ATLTA↓PTIVN
	nsp13b	nsp14					[27]	YKLQS↓QIVTG
nsp14	nsp15	[28]	FTRLQ↓SLENV	[28]	FTRLQ↓SLENV	[29]	TKVQG↓LENIA	
nsp15	nsp16	[30/2]	YPKLQ↓ASQAW	[30/2]	YPKLQ↓SSQAW	[30/2]	TFYPR↓LQASA	

#### 4.4 Subgenomic mRNA

Most frequent transcription regulating sequence (TRS) in MERS-CoV is TRS2 (5'-acgaac-3'). MERS-CoV transcribes 11 subgenomic mRNAs, with several ORFs translating polypeptide chains (ORF1.1 to ORF1.4) and several fusion proteins [Li et al 2019].

ORF3b is translated with an Internal Ribosome Entry Site (IRES). Other ORF encode some proteins (AP8b, AP7b, AP9b and AP14) with unknown transcription regulating sequences and functionality [Narayanan et al 2008]. ORF8b overlaps nucleocapsid gene (N) and encodes an accessory protein AP8b, called AP9b in SARS. Although it is not translated directly by any TRS, some studies have found antibodies specific to this protein in both in vitro and in vivo samples [Sharma et al 2011]

Tables 6 and 7 present a summary of ORF and proteins identified with Coronavirus.pro in MERS-CoV.

Table 6 - MERS-CoV open-reading frames (ORF) and proteins identified with Coronavirus.pro

mRNA-TRS <sup>(a)</sup>	j (bp)	ORF	proteins (Aa)		Fusion protein (Aa)		Comments
1-[2]	63	ORF1.1	pp1a	4391	-	-	[nsp1-nsp11]
			pp1ab	7078	-	-	[nsp1-nsp10], [nsp12-nsp16]
2-[1]	3904	ORF1.2	AP2	58	-	-	unknown
			pp2a	3022	pp2/nsp3	846	[nsp3a-nsp11]
			pp2ab	5709	pp2/nsp3	846	[nsp3a-nsp10], [nsp12-nsp16]
3-[1]	11815	ORF1.3	pp3a	487	pp3/nsp7	24	[nsp8-nsp11]
			pp3ab	3174	pp3/nsp7	24	[nsp8-nsp10], [nsp12-nsp16]
4-[2]	12751	ORF1.4	pp4a	226	pp4/nsp9	72	[nsp10-nsp11]
			pp4ab	2913	pp4/nsp9	72	[nsp10-nsp16]
5-[2]	21405	ORF2	Sp	1354	-	-	Surface glycoprotein spike precursor
			S	1010	-	-	Surface glycoprotein spike
			S0	344	-	-	S0 protease fragment
6-[2]	25521	ORF3	AP3	103	-	-	Accessory protein AP3
7-[1]	25843	ORF4a	AP4a	109	-	-	Accessory protein AP4a
8-[2]	25928	ORF4b	AP4b	246	-	-	Accessory protein AP4b
9-[2]	26833	ORF5	AP5	224	-	-	Accessory protein AP5
10-[2]	27583	ORF6	E	82	-	-	Envelope protein
		ORF7	M	219	-	-	Membrane protein
11-[2]	27838	ORF8a	N	413	-	-	Nucleocapsid phosphoprotein
			N1/N2/N3	223/166/25	-	-	N1/N2/N3 protease fragments

(a) Transcription regulating sequence: [1] TRS1 - 5'-cuaaac-3' // [2] TRS2 - 5'-acgaac-3'

Table 7 - MERS-CoV open-reading frames (ORF) with unknown TRS predicted by Coronavirus.pro

mRNA	j (bp)	ORF	proteins (Aa)		Comments
a	>25532	ORF3b	AP3b	66	Accessory protein AP3b, IRES translation
b	>28570	ORF8b	AP8b1-b7	113/105/90 61/55/53/49/37	Accessory proteins AP8b1-b7
c	>28990	ORF14	AP14a/b	42/108	Accessory proteins AP14a/b

SARS-CoV includes a transcription regulating sequence TRS which is not in MERS virus type, TRS3 (5'-cuaaacgaac-3'), also present in 2019-nCoV. SARS-CoV has several accessory protein (AP3a, AP6, AP7a), which are translated directly from mRNAs. In the case of AP6, although in some studies is named as nsp6, it is not processed by any protease, as other non-structural proteins. Other proteins, as AP11 is only characteristic from SARS-CoV. Furthermore, the shortest mRNA (ORF15), with a length of 263bp, translates no significant proteins and has an unknown functionality. Tables 8 and 9 show open-reading frames (ORF) and proteins (structural, non-structural, accessory and fusion) for SARS identified with Coronavirus.pro.

Table 8 - SARS-CoV open-reading frames (ORF) and proteins identified with Coronavirus.pro

mRNA-TRS <sup>(a)</sup>	j (bp)	ORF	proteins (Aa)		Fusion protein (Aa)		Comments
1-[3]	63	ORF1.1	pp1a	4383	-	-	[nsp1-nsp11]
			pp1ab	7074	-	-	[nsp1-nsp10], [nsp12-nsp16]
2-[1]	3665	ORF1.2	AP2	50	-	-	unknown
			pp2a	3095	pp2/nsp3	894	[nsp4-nsp11]
			pp2ab	5786	pp2/nsp3	894	[nsp4-nsp10], [nsp12-nsp16]
			pp2b	2628	pp3/nsp12	856	[nsp13-nsp16]
3-[1]	3800	ORF1.2	AP2	50	-	-	unknown
			pp2a	3095	pp2/nsp3	894	[nsp4-nsp11]
			pp2ab	5786	pp2/nsp3	894	[nsp4-nsp10], [nsp12-nsp16]
			pp2b	2628	pp3/nsp12	856	[nsp13-nsp16]
4-[3]	21482	ORF2b	S1p	1255	-	-	Surface glycoprotein Spike precursor
			S1	917	-	-	Surface glycoprotein Spike
			S0	339	-	-	S0 protease fragment
5-[1]	21913	ORF2a	S2p	1112	-	-	Surface glycoprotein Spike precursor
			S2	774	-	-	Surface glycoprotein Spike
			S0	339	-	-	S0 protease fragment
6-[2]	25260	ORF3a	AP3a	274	-	-	Accessory protein AP3a (SARS acsp3)
7-[2]	26109	ORF4	E	76	-	-	Envelope protein
8-[3]	26344	ORF5	M	221	-	-	Membrane protein
9-[2]	26913	ORF6	AP6	63	-	-	Accessory protein AP6 (SARS nsp6)
10-[2]	27267	ORF7a	AP7a	122	-	-	Accessory protein AP7a
11-[3]	27769	ORF8a	AP8a	40	-	-	Accessory protein AP8a
12-[2]	28106	ORF9a	N	422	-	-	Nucleocapsid phosphoprotein (p9a)
13-[1]	29489	ORF15	-	-	-	-	-

(a) Transcription regulating sequence: [1] TRS1 - 5'-cuaaac-3' // [2] TRS2 - 5'-acgaac-3' // [3] TRS3 - 5'-cuaaacgaac-3'

Table 9 - SARS-CoV open-reading frames (ORF) with unknown TRS predicted by Coronavirus.pro

mRNA	j (bp)	ORF	proteins (Aa)		Comments
a	> 25478	ORF3b	AP3b	175	Accessory protein AP3b, IRES translation
b	>25640	ORF3b	AP3b2	142	Accessory protein AP3b2
c	> 27273	ORF7b	AP7b	45	AP7b
d	> 27779	ORF8b	AP8b	85	AP8b
e	>28120	ORF9b	AP9b	98	Accessory protein AP9b, MA15 ExoN1
f	>28130	ORF11	AP11	73	AP11
g	> 28500	ORF14	AP14a/a	71/105	AP14a/b



2019-nCoV coronavirus presents relative differences in transcription and subgenomic mRNAs translation with other beta-coronavirus. This virus initiates transcription in 20 TRS sites, transcribing more types of subgenomic mRNAs than SARS/MERS. 2019-nCoV synthesizes around 9 types of fusion proteins, which are remarkably more than SARS/MERS coronavirus, and it is expected that the concentration of non-structural proteins, specially nsp12 (RdRp), nsp3 (PL2pro) and nsp5(3CLpro) is also higher. This fact could be related with the most severe health effects (toxicity) and highest infectivity on host patients than other betacoronavirus.

Furthermore, 2019-nCoV transcribes a mRNA (ORF15), with the shortest length (374bp), with no significant proteins encoded, as also present in SARS-CoV. Finally, 2019-nCoV virus translates another accessory protein, AP12, specific of this virus type.

Table 10 and 11 shows open-reading frames (ORF) and proteins (structural, non-structural, accessory and fusion) identified with Coronavirus.pro software in 2019-nCoV virus.

Table 10 - 2019-nCoV open-reading frames (ORF) and proteins identified with Coronavirus.pro

mRNA-TRS <sup>(a)</sup>	j (bp)	ORF	proteins (Aa)		Fusion proteins (Aa)		Comments
1-[3]	66	ORF1.1	pp1a	4406	-	-	[nsp1-nsp11]
			pp1ab	7097	-	-	[nsp1-nsp10], [nsp12-nsp16]
2-[1]	753	ORF1.2	pp2a	4233	pp2/nsp1	8	[nsp2-nsp11]
			pp2ab	6923	pp2/nsp1	8	[nsp2-nsp10], [nsp12-nsp16]
3-[1]	2358	ORF1.3	pp3a	3676	pp3/nsp2	89	[nsp3-nsp11]
			pp3ab	6366	pp3/nsp2	89	[nsp3-nsp10], [nsp12-nsp16]
4-[1]	3597	ORF1.4	AP2a	47	-	-	unknown
			AP2b	52	-	-	
			pp4a	3095	pp4/nsp3	893	[nsp3a-nsp11]
			pp4ab	5785	pp4/nsp3	893	[nsp3a-nsp10], [nsp12-nsp16]
5-[1]	6936	ORF1.5	pp5a	2153	pp5/nsp3a	170	[nsp3b-nsp11]
			pp5ab	4843	pp5/nsp3a	170	[nsp3b-nsp10], [nsp12-nsp16]
6-[1]	8655	ORF1.6	pp6a	1377	pp6/nsp4	234	[nsp5-nsp11]
			pp6ab	4067	pp6/nsp4	234	[nsp5-nsp10], [nsp12-nsp16]
7-[1]	13730	ORF1.7	pp7	2595	pp7/nsp12	824	[nsp13-nsp16]
8-[1]	16049	ORF1.8	pp8	1807	pp8/nsp12	34	[nsp13-nsp16]
9-[1]	18452	ORF1.9	pp9	1019	pp9/nsp14	375	[nsp15-nsp16]
10-[1]	20384	ORF1.10	pp10	374	pp10/nsp15	76	nsp16
11-[3]	21552	ORF2	Sp	1274	-	-	Surface glycoprotein spike precursor
			S	936	-	-	Surface glycoprotein spike
			S0	338	-	-	S0 protease fragment
12-[2]	25385	ORF3a	AP3a	276	-	-	(SARS ORF3/ORF3a/X1/U274)
13-[2]	26237	ORF4	E	76	-	-	Envelope protein
14-[3]	26469	ORF5	M	223	-	-	Transmembrane protein
			M1	183	-	-	M1 protease fragment
			M2	40	-	-	M2 protease fragment
15-[2]	27041	ORF6	AP6	62	-	-	(SARS ORF6/p6)
16-[2]	27388	ORF7a	AP7a	122	-	-	(SARS ORF8/U122/X4/ORF7a)
17-[1]	27644	ORF7b	AP7b	43	-	-	(SARS ORF7b)
18-[3]	27884	ORF8	AP8	122	-	-	(SARS ORF8)
19-[3]	28256	ORF9	N	420	-	-	Nucleocapsid phosphoprotein (p9a)
20-[1]	29530	ORF15	-	-	-	-	--

(a) Transcription regulating sequence: [1] TRS1 - 5'-cuaaac-3' // [2] TRS2 - 5'-acgaac-3' // [3] TRS3 - 5'-cuaaacgaac-3'

Table 11 - 2019-nCoV open-reading frames (ORF) with unknown TRS predicted by Coronavirus.pro

mRNA	j (bp)	ORF	proteins (Aa)		Comments
a	>25405	ORF3b1	AP3b1	42	AP3b1
		ORF3b2	AP3b2	34	AP3b2
b	>25457	ORF3b3	AP3b3	58	AP3b3
		ORF3b4	AP3b4	152	AP3b4
c	> 28274	ORF9b	AP9b	98	AP9b
d	> 28305	ORF11	AP11	73	AP11
e	> 28359	ORF12	AP12	43	AP12
f	> 28450	ORF14	AP14a/b	74/187	AP14a/b

In general to all of these betacoronaviruses, there are several accessory proteins which expression in vivo and in vitro has not been proved, and therefore its function is still unknown. It is the case of accessory protein AP2 in SARS/MERS and AP2a/b in 2019-nCoV.

#### 4.5 Coronavirus proteins

There are considerable differences between spike glycoproteins. For example, the number of spike glycoproteins is variable with MERS and also between SARS virus types. KY417149 (SARS) virus sequence encodes three spike glycoprotein precursors of different amino acid lengths (S1p, S2p and S3p), which later are processed by virus protease into S1, S2 and S3 spikes, with a common fragment S0. In the case of, NC004718 and AY278488 (SARS), it synthesizes two spike precursors (S1p and S2p), whereas 2019-nCoV and MERS, only one is processed. Spike glycoproteins from the same virus, although having different lengths, are estimated with a 100% identity, as observed from their identity matrices.

In the case of other proteins (N, M and E), it can be observed that this virus is more close related to SARS than to MERS, as also discussed previously. However, it presents also around 10% differences with other SARS, so it could be considered as a different virus type

All these proteins have been aligned with Clustal 1.2 to compare similarities [Higgins 1994, Brown et al 1998] (see Annex A for alignment details).

Table 12 compares structural proteins in these genome sequences of beta-coronaviruses.

Table 12 - Comparison of structural proteins of SARS-CoV, MERS-CoV and 2019-nCoV

#	#	Structural proteins length (Aa)													
#		S0	S1p	S1	S2p	S2	S3p	S3	N	M	E				
	1: NC019843 (MERS-CoV)	344	1353	1010	-	-	-	-	414	220	83				
	2: MN908947 (2019-nCoV)	338	1274	936	-	-	-	-	420	223	76				
	3: NC004718 (SARS-CoV)	338	1256	918	1113	775	-	-	423	222	77				
	4: AY278488 (SARS-CoV)	338	1256	918	1113	775	-	-	423	222	77				
	5: KY417149 (SARS-CoV)	338	1213	875	1242	904	578	240	423	222	77				
#	Spike glycoprotein (S) - Percent Identity Matrix - created by Clustal2.1														
	1: NC019843-S	100.00	27.98	29.60	27.98	29.60	28.27	27.36	26.91	44.77					
	2: NC004718-S1	27.98	100.00	100.00	99.67	99.74	70.57	75.98	74.19	92.92					
	3: NC004718-S2	29.60	100.00	100.00	99.74	99.74	73.94	78.19	78.19	92.92					
	4: AY278488-S1	27.98	99.67	99.74	100.00	100.00	70.79	76.21	74.41	92.92					
	5: AY278488-S2	29.60	99.74	99.74	100.00	100.00	74.06	78.32	78.32	92.92					
	6: MN908947-S	28.27	70.57	73.94	70.79	74.06	100.00	71.31	70.22	89.17					
	7: KY417149-S1	27.36	75.98	78.19	76.21	78.32	71.31	100.00	100.00	100.00					
	8: KY417149-S2	26.91	74.19	78.19	74.41	78.32	70.22	100.00	100.00	100.00					
	9: KY417149-S3	44.77	92.92	92.92	92.92	92.92	89.17	100.00	100.00	100.00					
#	S0 protein - Percent Identity Matrix - created by Clustal2.1														
	1: NC019843 (MERS-CoV)	100.00	41.14	41.74	41.74	42.04									
	2: MN908947 (2019-nCoV)	41.14	100.00	94.67	94.67	94.67									
	3: NC004718 (SARS-CoV)	41.74	94.67	100.00	100.00	98.22									
	4: AY278488 (SARS-CoV)	41.74	94.67	100.00	100.00	98.22									
	5: KY417149 (SARS-CoV)	42.04	94.67	98.22	98.22	100.00									
#	Nucleocapsid (N) - Percent Identity Matrix - created by Clustal2.1														
	1: NC019843	100.00	48.47	48.09	48.09	48.09									
	2: MN908947	48.47	100.00	89.29	89.52	89.52									
	3: KY417149	48.09	89.29	100.00	99.76	99.76									
	4: NC004718	48.09	89.52	99.76	100.00	100.00									
	5: AY278488	48.09	89.52	99.76	100.00	100.00									
#	Membrane (M) - Percent Identity Matrix - created by Clustal2.1														
	1: NC019843	100.00	40.00	42.27	42.73	42.73									
	2: MN908947	40.00	100.00	88.74	89.64	89.64									
	3: KY417149	42.27	88.74	100.00	98.20	98.20									
	4: NC004718	42.73	89.64	98.20	100.00	100.00									
	5: AY278488	42.73	89.64	98.20	100.00	100.00									
#	Envelope (E) - Percent Identity Matrix - created by Clustal2.1														
	1: NC019843	100.00	34.67	34.21	34.21	34.21									
	2: MN908947	34.67	100.00	96.05	96.00	96.05									
	3: KY417149	34.21	96.05	100.00	100.00	100.00									
	4: NC004718	34.21	96.00	100.00	100.00	100.00									
	5: AY278488	34.21	96.05	100.00	100.00	100.00									
#	Non-structural proteins length (Aa)														
#		nsp1/nsp2/nsp3/nsp3a/nsp3b/nsp4/nsp5/nsp6/nsp7/nsp8a/nsp8b/nsp9/nsp10/nsp11													
	1: NC019843 (MERS)	181	672	1361	178	348	508	305	292	84	198	-	110	141	14
	2: MN908947 (2019-nCoV)	181	638	1362	218	340	500	306	290	84	56	141	113	139	14
	3: NC004718 (SARS)	180	639	1385	219	340	500	307	289	84	56	141	113	140	13
	4: AY278488 (SARS)	180	638	1364	218	340	500	306	290	84	56	141	113	139	14
	5: KY417149 (SARS)	180	638	1582	-	340	500	306	290	84	56	141	113	139	14
		nsp12/nsp13a/nsp13b/nsp14/nsp15/nsp16													
	1: NC019843 (MERS)	933	236	362	524	340	306								
	2: MN908947 (2019-nCoV)	932	601	-	527	346	299								
	3: NC004718 (SARS)	931	601	-	527	346	299								
	4: AY278488 (SARS)	932	601	-	527	346	299								
	5: KY417149 (SARS)	932	601	-	527	346	299								

2019-nCoV protein sequences have been compared with SARS/MERS, through a distance estimator, calculated as  $id(\%) = (1-d/L) \times 100$ , where  $d$  is the Levenshtein distance between both sequences and  $L$  is the protein length of the SARS/MERS reference protein sequence. Although there are other distance estimators (Needleman-Wunsch, Smith-Waterman, Damerau-Levenshtein), the Levenshtein distance is an accurate estimator for high similar sequences.

In the case of MERS, no identity has been found in any protein (< 50%). Table 13 compares 2019-nCoV proteins with several virus genome sequences of SARS-CoV. As observed, most of non-structural proteins (nsp1, nsp3b and nsp5 to nsp16), accessory proteins AP7a/b and structural proteins M, N and E have the highest percents of similarity (>70%), proving that this virus is more close related with SARS type than MERS. Glycoprotein spike (S), most of accessory proteins (except AP7a/b, AP11 and AP14a) and non-structured proteins nsp2 to nsp3a and nsp4 have low similarity (< 50 %), proving that those proteins are characteristics of this virus type, and potential targets for specific vaccines and antiviral drugs. The fact that non-structural proteins are similar to SARS, indicates that antiviral drugs could be effective also to this virus.

Table 13 - Comparison of structural, non-structural and accessory proteins of 2019-nCoV with SARS-CoV

	Protein	NC004718	KY417149	AY278488
		13-AUG-2018	18-DEC-2017	01-SEP-2009
		% Id <sup>(1)</sup>	% Id <sup>(3)</sup>	% Id <sup>(2)</sup>
Structural	N	90.48	90.24	90.48
	M	90.58	89.24	90.58
	M1	91.26	90.16	91.80
	M2	82.50	85.00	85.00
	E	94.74	94.74	94.74
	Sp	< 50 %	< 50 %	< 50 %
	S	< 50 %	< 50 %	< 50 %
	S0	94.67	94.67	94.67
Non-structural	Nsp1	83.89	85.00	84.44
	Nsp2	< 50 %	< 50 %	< 50 %
	Nsp3	< 50 %	< 50 %	< 50 %
	Nsp3a	< 50 %	< 50 %	< 50 %
	Nsp3b	87.65	87.94	88.24
	Nsp4	< 50 %	< 50 %	< 50 %
	Nsp5	95.44	95.77	95.77
	Nsp6	87.54	87.20	87.20
	Nsp7	97.62	100	98.81
	Nsp8a	94.64	98.21	98.21
	Nsp8b	95.74	97.16	97.16
	Nsp9	95.58	97.35	97.35
	Nsp10	96.43	97.14	96.43
	Nsp11	84.62	76.92	76.92
	Nsp12	96.24	96.03	96.24
	Nsp13	99.50	99.50	99.67
Nsp14	94.69	95.64	95.07	
Nsp15	88.15	88.73	88.73	
Nsp16	93.31	94.31	93.31	
Accessory	AP2a	< 50 %	< 50 %	< 50 %
	AP2b	< 50 %	< 50 %	< 50 %
	AP3a	< 50 %	< 50 %	< 50 %
	AP3b1	< 50 %	< 50 %	< 50 %
	AP3b2	< 50 %	< 50 %	< 50 %
	AP3b3	< 50 %	< 50 %	< 50 %
	AP3b4	< 50 %	< 50 %	< 50 %
	AP6	< 50 %	67.74	< 50 %
	AP7a	85.25	87.70	85.25
	AP7b	79.55	81.82	79.55
	AP8	< 50 %	< 50 %	< 50 %
	AP9b	< 50 %	< 50 %	< 50 %
	AP11	76.71	73.97	76.71
	AP12	< 50 %	< 50 %	< 50 %
AP14a	74.32%	74.32	74.32	
AP14b	< 50 %	< 50 %	< 50 %	

As 3CLpro (nsp5) and RdRp (nsp12) have >90% similarities with SARS, some antiviral drugs, such as protease inhibitors or RNA-dependent RNA polymerase inhibitors could be effective to this virus type. Nevertheless, further comparisons would be required, including other types of estimators.

## 5. Conclusions

Coronavirus.pro software provides an accurate and reliable simulation model of Coronaviruses replication cycles: SARS/MERS/2019-nCoV. The code simulates transcription of subgenomic mRNAs, translation, protease cleavage, protein synthesis and virus assembly, including all fusion proteins.

As a result of the analysis, 2019-nCoV can be identified as a beta-coronavirus type SARS-CoV virus with high confidence, named SARS-CoV2, and it is consistent with other recent research analysis. Similarities have been found in 5'utr and 3'utr regions, protease cleavage sites and amino acid composition of both structural and non-structural proteins [Ceraolo and Giorgi 2020, Gorbalenya et al. 2020, Wu et al 2020] However, there are still differences between both coronavirus (SARS-CoV and 2019-nCoV), as the number of spike precursors and accessory proteins.

Coronavirus.pro is able to identify virus type and family, comparing virus genome and proteins with protein and RNA motifs databases. In this case, 2019-nCoV has been identified as a beta-coronavirus SARS in more than 70% than with MERS. However several differences have been found with SARS/MERS. 2019-nCoV has more transcription regulating sequences (TRS) interspaced in the genome and consequently, is producing more subgenomic mRNAs and more fusion proteins during RdRp transcription, which could explain more severe health effects and infectivity than SARS/MERS.

The software has identified those proteins characteristics of 2019-nCoV: Spike S, AP3a, AP3b, AP8, AP9b, AP12 and AP14b and nsp2/3/3a, with similarity < 50 % with other beta-coronaviruses.

Coronavirus.pro has predicted also some accessory proteins in all beta-coronavirus which have not been previously described, called AP2 in SARS-CoV and MERS-CoV, and AP2a/AP2b in 2019-nCoV, respectively. These proteins are encoded in the same genetic region as PL2pro protease (nsp3) and are translated before ORF1.2 (SARS/MERS) and ORF1.4 (2019-nCoV). If they are expressed in vivo or in vitro is not clearly understood, as they could be part of a leaky scanning/shunting mechanism.

The software has predicted some additional protease cleavage sites, giving place to some hypothetical proteins, as nsp3a↓nsp3b, nsp8a↓nsp8b, nsp13a↓nsp13b, M1↓M2 and N1↓N2↓N3. These cleavage sites must be discussed and supported in detail with other methods.

As a conclusion, Coronavirus.pro (2019-nCoV) is able to identify virus genomes and provides in short times useful results (FASTA files of virus proteins and RNA secondary structures). Future research will be focused in interactions between RNA and protein sequences and intracellular processes, fusion protein synthesis, RNA packaging and virus assembly, as carried out before with HIV virus with Monte Carlo simulations. These results will be applied to develop preventive actions (vaccines), diagnostic methods (real time RT-PCR or ELISA tests), and antiviral drugs (fusion inhibitors, RdRp inhibitors or PL2pro/3CLpro protease inhibitors).

## 6. References

- Aleanizy FS, Mohmed N, Algahtani FY and Mohamed RAEH. Outbreak of Middle East respiratory syndrome coronavirus in Saudi Arabia: a retrospective study. *BMC Infect Dis.* 2017; 17: 23. doi: 10.1186/s12879-016-2137-3
- Altschul SF, Gish W, Miller W, Myers EW and Lipman DJ. Basic local alignment search tool. *J Mol Biol.* 215:403-410. PubMed (1990)
- Apweiler R, Bairoch A, Wu CH, Barker WC, Boeckmann B, Ferro S, Gasteiger E, Huang H, Lopez R, Magrane M, Martin MJ, Natale DA, O'Donovan C, Redaschi N and Yeh L. UniProt: the Universal Protein knowledgebase. *Nucleic Acids Res* 32 D115-D119 (2004)
- Belouzard S, Chu VC and Whittaker GR. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. *Proc Natl Acad Sci USA* 106(14):5871-6 (2009)
- Bock LV, Caliskan N, Korniy N, Peske F, Rodnina MV and Grubmüller H. Thermodynamic control of -1 programmed ribosomal frameshifting. *Nature Communications* 10: 4598 (2019)
- Bonnal S, Boutonnet C, Prado-Lourenço and Vagner S. IRESdb: The Internal Ribosome Entry Site database. *Nucleic Acids Res*, 31(1): 427-428 (2003)
- Bouvet M, Debarnot C, Imbert I, Selisko B, Snijder EJ, Canard B et al. In vitro reconstruction of SARS-coronavirus mRNA cap methylation. *PLoS Pathog* 6 (2010)
- Bouvet M, Imbert I, Subissi L, Gluais L, Canard B, Decroly E. RNA 3' end mismatch excision by the severe acute respiratory syndrome coronavirus non-structural protein nsp10/nsp14 exoribonuclease complex. *Proc Natl Acad Sci USA* 109 (2012)
- Brian DA, Hogue BG and Kienzle TE. The Coronavirus Hemagglutinin Esterase Glycoprotein. The Coronaviridae. In: Siddell S.G. (eds) *The Coronaviridae. The Viruses.* Springer, Boston, MA (1995)
- Brown NP, Leroy C, Sander C. MView: A Web compatible database search or multiple alignment viewer. *Bioinformatics.* 14 (4):380-381 (1998)
- Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, and Madden TL. BLAST+: architecture and applications. *BMC Bioinformatics* 10:421. PubMed (2008)
- Ceraolo C and Giorgi FM. Genomic variance of the 2019-nCoV coronavirus. *Journal of Medical Virology. Short Comm.* (2020)
- Chen S, Chen L, Luo H, Sun T, Chen J, Ye F, Cai J, Shen J, Shen X and Jiang H. Enzymatic activity characterization of SARS coronavirus 3C-like protease by fluorescence resonance energy transfer technique. *Acta Pharmacologica Sinica* volume 26, p99–106 (2005)
- Chen Y, Liu Q and Guo D. Emerging coronaviruses: Genome structure, replication and pathogenesis. *Jour Med Virol* 92(4) (2020)
- Darty K, Denise A and Ponty Y. VARNA: Interactive drawing and editing of the RNA secondary structure. *Bioinformatics.* 2009 Aug 1; 25(15): 1974–1975.
- De Groot. Structure, function and evolution of the hemagglutinin-esterase proteins of corona- and toroviruses. *Glycoconj J* 23, 59–72 (2006). <https://doi.org/10.1007/s10719-006-5438-8>
- Dinman JD. Control of gene expression by translational recoding. *Adv Protein Chem Struct Biol.* 86, 129–149 (2012)

Doytchinova IA and Flower DR. Identifying candidate subunit vaccines using an alignment-independent method based on principal amino acid properties. *Vaccine* 25:856-866 (2007)

Doytchinova IA and Flower DR. Vaxijen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. *BMC Bioinformatics* 8:4 (2007)

Fehr AR and Perlman S. Coronaviruses: An Overview of their Replication and Pathogenesis. *Methods Mol Biol* 1282: 1–23 (2015) doi: 10.1007/978-1-4939-2438-7\_1

Giovanetti M, Benvenuto D, Angeletti S and Ciccozzi M. The first two cases of 2019-nCoV in Italy: Where they come from? *J Med Virol* 92(5): 518-521 (2020) <http://doi:10.1002/jmv.25699>

Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, Haagmans BL et al. Coronaviridae Study Group of The International Committee on Taxonomy of Viruses. *Nature Microbiology*. Consensus Statement (2020)

Gruber AR, Lorenz R, Bernhart SH, Neuboeck R and Hofacker IL. The Vienna RNA Websuite. *Nucleic Acids Res* 36: W70-W74 (2008)

He Y and Shibo J. Vaccine Design for Severe Acute Respiratory Syndrome Coronavirus. *Viral Immunology* 18(2) (2005)

Higgins DG. CLUSTAL V: multiple alignment of DNA and protein sequences. *Methods Mol. Biol.*, 25, 307–318 (1994)

Irigoyen N, Firth AE, Jones JD, Chung BYW, Siddell SG and Brierley I. High-Resolution Analysis of Coronavirus Gene Expression by RNA Sequencing and Ribosome Profiling. *PLOS Pathogens* (2016)

Jia HP, Look DC, Shi L, Hickey M, Pewe L, Netland J et al. ACE2 Receptor Expression and Severe Acute Respiratory Syndrome Coronavirus Infection Depend on Differentiation of Human Airway Epithelia. *J Virol* 79(23) 14614-14621 (2005)

Kiemer L, Lund O, Brunak S and Blom N. Coronavirus 3CLpro proteinase cleavage sites: Possible relevance to SARS virus pathology. *BMC Bioinformatics* 5:72 (2004)

Li F, Li W, Farzan M and Harrison SC. Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor. *Science* 309, issue 5742, pp 1864-1868 (2005)

Li G and De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV) *Nature Reviews*. Supplementary Information (2019)

Li Y, Hu C, Wu N, Yao H and Li L. Molecular Characteristics, functions and related pathogenicity of MERS-CoV proteins. *Engineering* 5, 940-947 (2019)

Liao X, Wang B and Kang Y. Novel coronavirus infection during the 2019-2020 epidemic: preparing intensive care units-the experience in Sichuan Province, China. *Intensive Care Med* 46(2):357-360 (2020) <http://doi:10.1007/s00134-020-05954-2>

Lin Y, Zhang X, Wu R and Lai M. The 3' Untranslated Region of Coronavirus RNA is required for subgenomic mRNA transcription from a defective interfering RNA. *Journal of Virology* 7236-7240 (1996)

Liu DX, Fung TS, Chong KKL, Shukla A, Hilgenfeld R. Accessory proteins of SARS-CoV and other coronaviruses. *Antiviral Research* 10, 97-109 (2014)

Madhugiri R, Karl N, Petersen D, Lamkiewicz K, Fricke M, Wend U, Scheuer R, Marz M and Ziebuhr J. Structural and functional conservation of cis-acting RNA elements in coronavirus 5'-terminal genome regions. *Virology* 517, 44-45 (2018)

Mokrejš M, Vopálenský V, Kolenatý O, Mašek T, Feketová Z, Sekyrová P, Škaloudová B, Kříž V and Pospíšek M. IRESite: the database of experimentally verified IRES structures ([www.iresite.org](http://www.iresite.org)) *Nucleic Acids Research* 34 D125-D130 (2006)

Moreno A, Lelli D, de Sabato L, Zaccaria G, Boni A, Sozzi E et al. Detection and full genome characterization of two beta CoV viruses related to Middle East respiratory syndrome from bats in Italy. *Virology Journal* 14, 239 (2017)

Nakagawa K, Lokugamage KG and Makino S. Viral and Cellular mRNA translation in Coronavirus-Infected Cells. *Adv Virus Res* 96: 165-192 (2016)

Narayanan K, Huang C and Makino S. SARS coronavirus Accessory Proteins. *Virus Res* 133(1): 113-121 (2008)

National Center for Biotechnology Information (NCBI)[Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; [1988] – [cited 2017 Apr 06]. Available from: <https://www.ncbi.nlm.nih.gov/>

Oany AR, Emran AA and Jyoti TP. Design of an epitope-based peptide vaccine against spike protein of human coronavirus: An in silico approach. *Drug, Development and Therapy*. 1139-1149 (2014)

Oxford J, Kellam P and Collier L. *Human Virology* 5<sup>th</sup> Edition (2016) Oxford Publishing

Peng YH, Lin CH, Lin CN, Lo CY, Tsai TL and Wu HY. Characterization of the Role of Hexamer AGUAAA and Poly(A) Tail in Coronavirus Polyadenylation. *PLoS One* 11(10) (2016)

Plant E, Pérez-Alvarado, Jacobs JL, Mukhopadhyay, Hennig M and Dinman JD. A three-stemmed mRNA pseudoknot in the SARS Coronavirus Frameshift Signal. *PLoS Biol* 3(6) (2005)

Ramos-Pascual M. *Simulation of HIV-1 virus cycle with fortran 90 / C++*. Lambert Academic Publishing (LAP) ISBN: 978-3-659-78218-3 (2019)

Ramos-Pascual M. *Simulation of HIV-1 virus infection of a CD4+T lymphocyte by Monte Carlo*. Grin Publishing. ISBN (Ebook) 978-3-346-05467-8 (2019)

Raoult D, Zumla A, Locatelli F, Ippolito G and Kroemer G. Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses. *Cell Stress* 2 (2020) <http://doi: 10.15698/cst2020.04.216>

Sawicki AG, Sawicki DL and Siddell SG. A Contemporary View of Coronavirus Transcription. *J Virol* 8(1):20-29 (2007)

Sethna PB, Hung SL, Brian DA. Coronavirus subgenomic minus-strand RNAs and the potential for mRNA replicons. *Proc Natl Acad Sci USA*. Vol 86 5626-5630 (1989)

Sharma K, Akerström S, Sharma AK, Chow VTK, Teow S, Abrenica B, Booth SA, Booth TF, Mirazimi A and Lal SK. SARS-CoV 9b Protein Diffuses into Nucleus, Undergoes Active Crm1 Mediated Nucleocytoplasmic Export and Triggers Apoptosis When Retained in the Nucleus. *PLoS One* 6(5) (2011)

Song J, Tan H, Perry AJ, Akutsu T, Webb GI, Whisstock JC and Pike R. PROSPER: An Integrated feature-based tool for predicting protease substrate cleavage sites. *PLoS ONE* 7(11): e50300 <https://doi.org/10.1371/journal.pone.0050300>



- Snijder EJ, Bredenbeek PJ, Dobbe JC, Thiel V, Ziebuhr J, Poon LL, Guan Y, Rozanov M, Spaan WJ and Gorbalenya AE. Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. *J. Mol. Biol.* 331 (5), 991-1004 (2003)
- Sulea T, Lindner HA, Purisima EO and Ménard R. Binding site-based classification of coronaviral papain-like proteases. *Proteins* 62(3) (2006)
- van Boheemen S, de Graaf M, Lauber C, Bestebroer TM, Raj VS, Zaki AM, Osterhaus AD, Haagmans BL, Gorbalenya AE, Snijder EJ and Fouchier RA. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. *MBio* 3 (6), e00473-12 (2012)
- Vijayanand P, Wilkins E, Woodhead M. Severe acute respiratory syndrome (SARS): a review. *Clin Med (Lond)* 2004 4(2):152-60
- Wang, H., Yang, P., Liu, K., Guo, F., Zhang, Y., Zhang, G., Jiang, C., 2008. SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway. *Cell research* 18(2), 290-301.
- Wang Q, Wong G, Lu G, Yan J and Gao GF. MERS-CoV spike protein: Targets for vaccines and therapeutics. *Antiviral Research* 133, 165-177 (2016)
- Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, Heer FT, de Beer, TAP, Rempfer C, Bordoli L, Lepore R, Schwede T. SWISS-MODEL: homology modelling of protein structures and complexes. *Nucleic Acids Res.* 46, W296-W303 (2018)
- Wu A, Peng Y, Huang B et al. Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) originating in China. *Cell Host & Microbe* (2020)
- Wu Z and McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA.* 2020 Feb 24. doi: 10.1001/jama.2020.2648.
- Xu J, Hu J, Wang J, Han Y, Hu Y, Wen J, Li Y, Ji J et al. Genome Organization of the SARS-CoV. *Genomics Proteomics Bioinformatics.* 1(3): 226-235 (2003)
- Yang D, Leibowitz JL, The Structure and Functions of Coronavirus Genomic 3' and 5' Ends, *Virus Research*, doi:10.1016/j.virusres.2015.02.025
- Zeng Q, Langereis MA, van Vliet ALW, Huizinga EG and de Groot RJ. Structure of coronavirus hemagglutinin-esterase offers insight into corona and influenza virus evolution. *Proc Natl Acad Sci USA* Jul 1; 105(26): 9065–9069. (2008)
- Zhu N et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med.* 2020 Feb 20;382(8):727-733. doi: 10.1056/NEJMoa2001017
- Zu ZY, Jiang MD, Xu PP, Chen W, Ni QQ, Lu GM, Zhang LJ. Coronavirus Disease 2019 (COVID-19): A perspective from China. *Radiology.* 2020 Feb 21:200490. doi: 10.1148/radiol.2020200490

# Annex A - Sequence alignment of Spike Glycoprotein

## A.1 Spike glycoproteins (S)

Reference sequence (1): NC019843-S  
 Identities normalised by aligned length.  
 Colored by: identity

	cov	pid	1 [
1 NC019843-S	100.0%	100.0%	MIHSVFLIMFLITPESYVDVGPDSVKSACLEVDIQOTFFDKTWERPLDYSKADGLIYPQ
2 NC004718-S1	88.1%	24.0%	--MFIFLLFLTL-----TSGSDLDRCCTFDVQAP-----NYTQHTSSMRGVYYPDE
3 NC004718-S2	74.3%	26.5%	-----TSGSDLDRCCTFDVQAP-----NYTQHTSSMRGVYYPDE
4 AY278488-S1	88.1%	24.0%	--MFIFLLFLTL-----TSGSDLDRCCTFDVQAP-----NYTQHTSSMRGVYYPDE
5 AY278488-S2	74.3%	26.5%	-----TSGSDLDRCCTFDVQAP-----NYTQHTSSMRGVYYPDE
6 MN908947-S	89.3%	24.5%	--MFVFLV--LL-----PL--VSSQCVNLTRRQQL-----EPAYTNSFTRGVYYPDK
7 KY417149-S1	84.0%	23.4%	-----MDKFSSSRRRCVYVYND
8 KY417149-S2	86.8%	22.8%	--MKVLIVLLCL-----GLVTAQDGCCHISTKPKQP-----LMDKFSSSRRRCVYVYND
9 KY417149-S3	23.7%	43.5%	-----LMDKFSSSRRRCVYVYND
consensus/100%			.....
consensus/90%			.....
consensus/80%			.....
consensus/70%			.....

	cov	pid	81
1 NC019843-S	100.0%	100.0%	DHCDMYVYSAGHATCTTPQKLFVANYSDVQEFANGFVVRIGAAANSTCTVIISPESTSAT
2 NC004718-S1	88.1%	24.0%	NVTG--FHTIN-----HT----FGNPVIEPKKDCIYFAATE-----K
3 NC004718-S2	74.3%	26.5%	-----HT----FDNPVIEPKKDCIYFAATE-----K
4 AY278488-S1	88.1%	24.0%	NVTG--FHTIN-----HT----FDNPVIEPKKDCIYFAATE-----K
5 AY278488-S2	74.3%	26.5%	-----HT----FDNPVIEPKKDCIYFAATE-----K
6 MN908947-S	89.3%	24.5%	NVTW--FHAIHVSCTNGTKR-----FDNPVLEFNDGVYFASTE-----K
7 KY417149-S1	84.0%	23.4%	NLTR--VLSFNMDS--ATKVY-----FDNPTLPEKDCIYFAATE-----K
8 KY417149-S2	86.8%	22.8%	NLTR--VLSFNMDS--ATKVY-----FDNPTLPEKDCIYFAATE-----K
9 KY417149-S3	23.7%	43.5%	-----FDNPTLPEKDCIYFAATE-----K
consensus/100%			.....
consensus/90%			.....
consensus/80%			.....
consensus/70%			.....

	cov	pid	161
1 NC019843-S	100.0%	100.0%	KMGRFFNHTLVLLEDGCGTLIRAFYCI--LEPRSGNHCAGNSYTSFATYHTPATDCSDGN
2 NC004718-S1	88.1%	24.0%	-----VIIINNSTNVVIRACNFELCDNFFFAVSKEMG
3 NC004718-S2	74.3%	26.5%	-----VIIINNSTNVVIRACNFELCDNFFFAVSKEMG
4 AY278488-S1	88.1%	24.0%	-----VIIINNSTNVVIRACNFELCDNFFFAVSKEMG
5 AY278488-S2	74.3%	26.5%	-----VIIINNSTNVVIRACNFELCDNFFFAVSKEMG
6 MN908947-S	89.3%	24.5%	-----LLIVNATNVVIVKVEQFCNDPFLGVYHKM
7 KY417149-S1	84.0%	23.4%	-----AIVVNSTHIIIRVCFNLCKEPMYAISNEQH
8 KY417149-S2	86.8%	22.8%	-----AIVVNSTHIIIRVCFNLCKEPMYAISNEQH
9 KY417149-S3	23.7%	43.5%	-----AIVVNSTHIIIRVCFNLCKEPMYAISNEQH
consensus/100%			.....
consensus/90%			.....
consensus/80%			.....
consensus/70%			.....

	cov	pid	241
1 NC019843-S	100.0%	100.0%	TFEYITYNITEDEILEWFGITQTAQGVHLFSSRYVDLYGG-----NM-----FOE
2 NC004718-S1	88.1%	24.0%	TPEYISDAFSLDVSEKSGNFKHLREFVFKNKDGFLYVYKGYQPIDVVRDLPSGFNTLKPIF
3 NC004718-S2	74.3%	26.5%	TPEYISDAFSLDVSEKSGNFKHLREFVFKNKDGFLYVYKGYQPIDVVRDLPSGFNTLKPIF
4 AY278488-S1	88.1%	24.0%	TPEYISDAFSLDVSEKSGNFKHLREFVFKNKDGFLYVYKGYQPIDVVRDLPSGFNTLKPIF
5 AY278488-S2	74.3%	26.5%	TPEYISDAFSLDVSEKSGNFKHLREFVFKNKDGFLYVYKGYQPIDVVRDLPSGFNTLKPIF
6 MN908947-S	89.3%	24.5%	TPEYVSPFLMDLEKQGNFKNLRREFVFKNIDGFLYVYKGYQPIDVVRDLPSGFNTLKPIF
7 KY417149-S1	84.0%	23.4%	TYDRVQSFLDTPAQTCGNFKDLREYVFKNKDGFLSVYNAYSPIDIPRGLPVGFVSLKPII
8 KY417149-S2	86.8%	22.8%	TYDRVQSFLDTPAQTCGNFKDLREYVFKNKDGFLSVYNAYSPIDIPRGLPVGFVSLKPII
9 KY417149-S3	23.7%	43.5%	-----TYDRVQSFLDTPAQTCGNFKDLREYVFKNKDGFLSVYNAYSPIDIPRGLPVGFVSLKPII
consensus/100%			.....
consensus/90%			.....
consensus/80%			.....
consensus/70%			.....



	cov	pid	401
1 NC019843-S	100.0%	100.0%	VEQLE-GVPCDFSPILLSG-TPEOVYNFKRLVFTNCNYNLTKLLS-FSVNDFTCSDLSPAAI
2 NC004718-S1	88.1%	24.0%	VRFPNITNLCPPGGEVFNATKFFSVYAWERKKLSNCVADYSVLYNSTFFFSTFKCYGVSATKI
3 NC004718-S2	74.3%	26.5%	VRFPNITNLCPPGGEVFNATKFFSVYAWERKKLSNCVADYSVLYNSTFFFSTFKCYGVSATKI
4 AY278488-S1	88.1%	24.0%	VRFPNITNLCPPGGEVFNATKFFSVYAWERKKLSNCVADYSVLYNSTFFFSTFKCYGVSATKI
5 AY278488-S2	74.3%	26.5%	VRFPNITNLCPPGGEVFNATKFFSVYAWERKKLSNCVADYSVLYNSTFFFSTFKCYGVSATKI
6 MN908947-S	89.3%	24.5%	VRFPNITNLCPPGGEVFNATRFASVYAWNRKRI-SNCVADYSVLYNSASFSTFKCYGVSPTKI
7 KY417149-S1	84.0%	23.4%	IRFPNITNRCPPDKVFNASRFENVYAWERTKISDCVADYTVLYNSTFSFSTFKCYGVSPSKI
8 KY417149-S2	86.8%	22.8%	IRFPNITNRCPPDKVFNASRFENVYAWERTKISDCVADYTVLYNSTFSFSTFKCYGVSPSKI
9 KY417149-S3	23.7%	43.5%	-----
consensus/100%			
consensus/90%			
consensus/80%			
consensus/70%			

lc.sp.ss.CsFs.lhsu.p.spVYsapRhhhosCshshohLhs.h.hssFpC.tlSsstl  
 lRFPNITNRCPPDKVFNASRFENVYAWERTKISDCVADYTVLYNSTFSFSTFKCYGVSPSKI

	cov	pid	481
1 NC019843-S	100.0%	100.0%	KSDLVSSVAGPISQFNYKQSFNSNPTCLILATVEHNLITTKPLKYSYINKCSRLLSDDRTE
2 NC004718-S1	88.1%	24.0%	VRQIAPGQTEGVIADYNYKLPDDFMGCVLAWNTRNIDASTGNYNKYRYLRHGKLRPFERI
3 NC004718-S2	74.3%	26.5%	VRQIAPGQTEGVIADYNYKLPDDFMGCVLAWNTRNIDASTGNYNKYRYLRHGKLRPFERI
4 AY278488-S1	88.1%	24.0%	VRQIAPGQTEGVIADYNYKLPDDFMGCVLAWNTRNIDASTGNYNKYRYLRHGKLRPFERI
5 AY278488-S2	74.3%	26.5%	VRQIAPGQTEGVIADYNYKLPDDFMGCVLAWNTRNIDASTGNYNKYRYLRHGKLRPFERI
6 MN908947-S	89.3%	24.5%	VRQIAPGQTEGVIADYNYKLPDDFTGCVLAWNSNLDKSVGGNYYLYRFRKSNLKPFFERI
7 KY417149-S1	84.0%	23.4%	VRQVAPGETEGVIADYNYKLPDDFTGCVLAWNTAKQDQ-----GQYYRSSRKTTLKPFERI
8 KY417149-S2	86.8%	22.8%	VRQVAPGETEGVIADYNYKLPDDFTGCVLAWNTAKQDQ-----GQYYRSSRKTTLKPFERI
9 KY417149-S3	23.7%	43.5%	-----
consensus/100%			
consensus/90%			
consensus/80%			
consensus/70%			

hplplusupsG.TupaNYK.s.s.sClhhss.p.t.....hpY.Yh.ppt.Lps.cp-  
 VRQIAPGQTEGVIADYNYKLPDDFMGCVLAWNtp.Dt.....hpYhYR.R+spL+PFERI

	cov	pid	561
1 NC019843-S	100.0%	100.0%	T-VWEDGDYYRKKQLSLEGGGRLVAS-CSTVAMTEQLQMGFGITVOYGTDFNSVCPRLEFAN
2 NC004718-S1	88.1%	24.0%	NCYWPLND-----YGFYTTTIGIGYQPYRVVVLSEFELL---NAPATVCGP----
3 NC004718-S2	74.3%	26.5%	NCYWPLND-----YGFYTTTIGIGYQPYRVVVLSEFELL---NAPATVCGP----
4 AY278488-S1	88.1%	24.0%	NCYWPLND-----YGFYTTTIGIGYQPYRVVVLSEFELL---NAPATVCGP----
5 AY278488-S2	74.3%	26.5%	NCYWPLND-----YGFYTTTIGIGYQPYRVVVLSEFELL---NAPATVCGP----
6 MN908947-S	89.3%	24.5%	NCYFPLQS-----YGFQPTNCGVYQPYRVVVLSEFELL---HAPATVCGP----
7 KY417149-S1	84.0%	23.4%	--VRTLST-----YDFYPTVPIEQATRVVVLSEFELL---NAPATVCGP----
8 KY417149-S2	86.8%	22.8%	--VRTLST-----YDFYPTVPIEQATRVVVLSEFELL---NAPATVCGP----
9 KY417149-S3	23.7%	43.5%	-----
consensus/100%			
consensus/90%			
consensus/80%			
consensus/70%			

..hh.ts.....hsa.ssss.tht.hc.l.huEtllh....psssoVCs.....  
 ..hhsLss.....YsFhsTssltYQshRVVVLSEFELL....sAPATVCGP.....

	cov	pid	641
1 NC019843-S	100.0%	100.0%	SGRQVFNCTAVGVRRQRFVYDAYQNLVGYYSDDENYYCLRACVSVPSVVIYD--KETI
2 NC004718-S1	88.1%	24.0%	TGTGVLTPSSKRFQPFQFGRDVSDFDTSVDRPKTSEILDISPCAFGGVSVITPGTNASS
3 NC004718-S2	74.3%	26.5%	TGTGVLTPSSKRFQPFQFGRDVSDFDTSVDRPKTSEILDISPCAFGGVSVITPGTNASS
4 AY278488-S1	88.1%	24.0%	TGTGVLTPSSKRFQPFQFGRDVSDFDTSVDRPKTSEILDISPCAFGGVSVITPGTNASS
5 AY278488-S2	74.3%	26.5%	TGTGVLTPSSKRFQPFQFGRDVSDFDTSVDRPKTSEILDISPCAFGGVSVITPGTNASS
6 MN908947-S	89.3%	24.5%	TGTGVLTPSSKRFQPFQFGRDIADTT-DAVRDPQTLLEILDITPCSFGGVSVITPGTNASS
7 KY417149-S1	84.0%	23.4%	KGTGVLTPSSKRFQSFQFGRDTSDFDTSVDRPQTLQILDITPCSFGGVSVITPGTNASS
8 KY417149-S2	86.8%	22.8%	KGTGVLTPSSKRFQSFQFGRDTSDFDTSVDRPQTLQILDITPCSFGGVSVITPGTNASS
9 KY417149-S3	23.7%	43.5%	-----
consensus/100%			
consensus/90%			
consensus/80%			
consensus/70%			

pGpGVhp.ssthh...QpFshDh.p.h.s.hpD..s.phhslpsCs.ssSVIhS..ptor  
 pGTGVLTPSSKRFQSFQFGRDTSDFDTSVDRPQTLQILDITPCSFGGVSVITPGTNASS



	cov	pid	801
1 NC019843-s	100.0%	100.0%	LQV-DQINSSYFKLSIPTNFSEGVTOEYIQTTIQKVTVDCKQYVCGNFQKCEQLIREYGF
2 NC004718-s1	88.1%	24.0%	LGADSSIAYSNNNTIAIPTNFSISITTEVMPVSMKTSVDCNMYICGDSTECANLLLOYGSE
3 NC004718-s2	74.3%	26.5%	LGADSSIAYSNNNTIAIPTNFSISITTEVMPVSMKTSVDCNMYICGDSTECANLLLOYGSE
4 AY278488-s1	88.1%	24.0%	LGADSSIAYSNNNTIAIPTNFSISITTEVMPVSMKTSVDCNMYICGDSTECANLLLOYGSE
5 AY278488-s2	74.3%	26.5%	LGADSSIAYSNNNTIAIPTNFSISITTEVMPVSMKTSVDCNMYICGDSTECANLLLOYGSE
6 MN908947-s	89.3%	24.5%	LGAENSVAYSNNNSIAIPTNFSISITTEVMPVSMKTSVDCNMYICGDSTECANLLLOYGSE
7 KY417149-s1	84.0%	23.4%	LGAENSIAYANNSIAIPTNFSISITTEVMPVSMKTSVDCNMYICGDSTECANLLLOYGSE
8 KY417149-s2	86.8%	22.8%	LGAENSIAYANNSIAIPTNFSISITTEVMPVSMKTSVDCNMYICGDSTECANLLLOYGSE
9 KY417149-s3	23.7%	43.5%	LGAENSIAYANNSIAIPTNFSISITTEVMPVSMKTSVDCNMYICGDSTECANLLLOYGSE
consensus/100%			lts.sppls.u..pluIPTNFohultpEhh.sohtksoVDCp.YlCcss.pcCtpLLhpYGpF
consensus/90%			lts.sppls.u..pluIPTNFohultpEhh.sohtksoVDCp.YlCcss.pcCtpLLhpYGpF
consensus/80%			LGA-sSIAYunNoIAIPTNFSISITTElhpVSMskKTSVDCsMYICGDSPeCuNLLLOYGSE
consensus/70%			LGA-sSIAYunNoIAIPTNFSISITTEVMPVSMuKTSVDCsMYICGDSPeCuNLLLOYGSE

	cov	pid	881
1 NC019843-s	100.0%	100.0%	RNLFASVKSQSSPIIPGFGDFNLTLEPVSISTGSRARSALIEDLLFDKVTIADPGYMC
2 NC004718-s1	88.1%	24.0%	REVFAQVKQMYKPTLKYFGGF-NFSQILPD---PLKPTKRSFIEDLLFNKVTIADAGFMK
3 NC004718-s2	74.3%	26.5%	REVFAQVKQMYKPTLKYFGGF-NFSQILPD---PLKPTKRSFIEDLLFNKVTIADAGFMK
4 AY278488-s1	88.1%	24.0%	REVFAQVKQMYKPTLKYFGGF-NFSQILPD---PLKPTKRSFIEDLLFNKVTIADAGFMK
5 AY278488-s2	74.3%	26.5%	REVFAQVKQMYKPTLKYFGGF-NFSQILPD---PLKPTKRSFIEDLLFNKVTIADAGFMK
6 MN908947-s	89.3%	24.5%	QEVFAQVKQIYKTPAIKDFGGF-NFSQILPD---PSKPTKRSFIEDLLFNKVTIADAGFIK
7 KY417149-s1	84.0%	23.4%	QEVFAQVKQMYKTPAIKDFGGF-NFSQILPD---PSKPTKRSFIEDLLFNKVTIADAGFMK
8 KY417149-s2	86.8%	22.8%	QEVFAQVKQMYKTPAIKDFGGF-NFSQILPD---PSKPTKRSFIEDLLFNKVTIADAGFMK
9 KY417149-s3	23.7%	43.5%	QEVFAQVKQMYKTPAIKDFGGF-NFSQILPD---PSKPTKRSFIEDLLFNKVTIADAGFMK
consensus/100%			pplFApVkp..poP.l..FGG..Nho.l.Ps...s.p.otrShIEDLLFSKVTLADsGahp
consensus/90%			pplFApVkp..poP.l..FGG..Nho.l.Ps...s.p.otrShIEDLLFSKVTLADsGahp
consensus/80%			pEVFAQVKQhYKTPslk.FGGF.NFSQILPD...P.KPKRSFIEDLLFNKVTIADAGFMK
consensus/70%			pEVFAQVKQMYKTPslk.FGGF.NFSQILPD...P.KPKRSFIEDLLFNKVTIADAGFMK

	cov	pid	961
1 NC019843-s	100.0%	100.0%	QYVAGYKVLPPLLDVMNEAAYTSSLLCSLAGVCGWTAGLSSFAAIPFAQSIFYRLNGVGITC
2 NC004718-s1	88.1%	24.0%	QKFNGLTVLPPLLTDDMIAAYTAALVSGTATACWTFGAGAALQIFFAMQMAYRFNGIGVTC
3 NC004718-s2	74.3%	26.5%	QKFNGLTVLPPLLTDDMIAAYTAALVSGTATACWTFGAGAALQIFFAMQMAYRFNGIGVTC
4 AY278488-s1	88.1%	24.0%	QKFNGLTVLPPLLTDDMIAAYTAALVSGTATACWTFGAGAALQIFFAMQMAYRFNGIGVTC
5 AY278488-s2	74.3%	26.5%	QKFNGLTVLPPLLTDDMIAAYTAALVSGTATACWTFGAGAALQIFFAMQMAYRFNGIGVTC
6 MN908947-s	89.3%	24.5%	QKFNGLTVLPPLLTDEMIAQYTSALLAGTITSCWTFGAGAALQIFFAMQMAYRFNGIGVTC
7 KY417149-s1	84.0%	23.4%	QKFNGLTVLPPLLTDDMIAAYTAALVSGTATACWTFGAGAALQIFFAMQMAYRFNGIGVTC
8 KY417149-s2	86.8%	22.8%	QKFNGLTVLPPLLTDDMIAAYTAALVSGTATACWTFGAGAALQIFFAMQMAYRFNGIGVTC
9 KY417149-s3	23.7%	43.5%	QKFNGLTVLPPLLTDDMIAAYTAALVSGTATACWTFGAGAALQIFFAMQMAYRFNGIGVTC
consensus/100%			QhhsGhpVLPPLLhsspm.AEYTuulLuuhhssCWThGhuuhhtIFFA.phhYRhNgIGlTC
consensus/90%			QhhsGhpVLPPLLhsspm.AEYTuulLuuhhssCWThGhuuhhtIFFA.phhYRhNgIGlTC
consensus/80%			QKFNGLTVLPPLLTD-MIAAYTuAlLuGTATuCWTFGAGAALQIFFAMQMAYRFNGIGVTC
consensus/70%			QKFNGLTVLPPLLTDDMIAAYTAALVSGTATACWTFGAGAALQIFFAMQMAYRFNGIGVTC

	cov	pid	1041	] 1044
1 NC019843-s	100.0%	100.0%	AMQT	
2 NC004718-s1	88.1%	24.0%	QIQE	





### A.3 Envelope protein (E)

Reference sequence (1): NC019843  
 Identities normalised by aligned length.  
 Colored by: identity

	cov	pid	1	[
1 NC019843	100.0%	100.0%	-LFFVQERIGLFIIVNFFLFTVVCATLLVCMAPLTAIRLCVOCMTGFNTLLVOPALYLYN	
2 MN908947	91.5%	32.9%	MYSEVSEETGTLIVNSVLLFLAFVVFLLVTLAILTAIRLCAYCCNIVNVS LVKPSFYVYS	
3 KY417149	92.7%	32.9%	MYSEVSEETGTLIVNSVLLFLAFVVFLLVTLAILTAIRLCAYCCNIVNVS LVKPTVYVYS	
4 NC004718	92.7%	33.3%	-YSEVSEETGTLIVNSVLLFLAFVVFLLVTLAILTAIRLCAYCCNIVNVS LVKPTVYVYS	
5 AY278488	92.7%	32.9%	MYSEVSEETGTLIVNSVLLFLAFVVFLLVTLAILTAIRLCAYCCNIVNVS LVKPTVYVYS	
consensus/100%			.hsFVpEchGhhIVN.hllhllshslhLLVshAhLTAIRLCS.ChshhNs.LVpPshYLYS	
consensus/90%			.hsFVpEchGhhIVN.hllhllshslhLLVshAhLTAIRLCS.ChshhNs.LVpPshYLYS	
consensus/80%			.YSEVSEETGTLIVNSVLLFLAFVVFLLVTLAILTAIRLCAYCCNIVNVS LVKP <del>OLY</del> VYS	
consensus/70%			.YSEVSEETGTLIVNSVLLFLAFVVFLLVTLAILTAIRLCAYCCNIVNVS LVKP <del>OLY</del> VYS	
			81	] 83
1 NC019843	100.0%	100.0%	WVX	
2 MN908947	91.5%	32.9%	---	
3 KY417149	92.7%	32.9%	---	
4 NC004718	92.7%	33.3%	---	

MView 1.63, Copyright © 1997-2018 [Nigel P. Brown](#)





## A.5 Nucleocapsid (N)

Reference sequence (1): NC019843  
 Identities normalised by aligned length.  
 Colored by: identity

	cov	pid	1 [
1 NC019843	100.0%	100.0%	-----MAS PAAPRAVSFADNNDI T N T N I-----SRCRGRNPKPRAAENNTVSWYTGLTQHGF
2 MN908947	94.7%	43.0%	MSDNGPQ-NQRNAPRITFGGPDSTGSNQNGERSGARSKORRPPQGLENNNTASWFTALTOHGF
3 KY417149	94.9%	42.6%	MSDNGPQSNQRSAPRITFGGPDSTDNQNGGRNGTRPKORRPPQGLENNNTASWFTALTOHGF
4 NC004718	94.9%	42.6%	MSDNGPQSNQRSAPRITFGGPDSTDNQNGGRNGARPKORRPPQGLENNNTASWFTALTOHGF
5 AY278488	94.9%	42.6%	MSDNGPQSNQRSAPRITFGGPDSTDNQNGGRNGARPKORRPPQGLENNNTASWFTALTOHGF
consensus/100%			.....s.tss.tlcFussSD.TssN.....stsRs+p.+PpuhFNNTsSwaTuLTQHGF
consensus/90%			.....s.tss.tlcFussSD.TssN.....stsRs+p.+PpuhFNNTsSwaTuLTQHGF
consensus/80%			MSDNGPQuNQRuAPRITFGGPDSTssNQNGtrSgursKORRPPQGLENNNTASWFTALTOHGF
consensus/70%			MSDNGPQuNQRuAPRITFGGPDSTssNQNGtrSgursKORRPPQGLENNNTASWFTALTOHGF

	cov	pid	81
1 NC019843	100.0%	100.0%	PAQNAGYWRRODRKINTGNG-ITKQLAPRWYFYYTCTGPEAALPFRVAVKDGIVVWVEDGATDZ
2 MN908947	94.7%	43.0%	PDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLCTGPEACLPGYGANKDGIIVVATEGALNI
3 KY417149	94.9%	42.6%	PDDQIGYYRRATRRVRGGDGKMKELSPRWYFYYLCTGPEASLPGYGANKGIVVWVATEGALNI
4 NC004718	94.9%	42.6%	PDDQIGYYRRATRRVRGGDGKMKELSPRWYFYYLCTGPEASLPGYGANKGIVVWVATEGALNI
5 AY278488	94.9%	42.6%	PDDQIGYYRRATRRVRGGDGKMKELSPRWYFYYLCTGPEASLPGYGANKGIVVWVATEGALNI
consensus/100%			PspphCYARRtsr+lpSgsG.hKpLuPRWYFYYhCTGPEAuLPatASK-GIIVWtp-GAhs
consensus/90%			PspphCYARRtsr+lpSgsG.hKpLuPRWYFYYhCTGPEAuLPatASK-GIIVWtp-GAhs
consensus/80%			PDDQIGYYRRATRRIRGGDGKMK-LSPRWYFYYLCTGPEAuLPYGANK-GIVVWVATEGALNI
consensus/70%			PDDQIGYYRRATRRIRGGDGKMK-LSPRWYFYYLCTGPEAuLPYGANK-GIVVWVATEGALNI

	cov	pid	161
1 NC019843	100.0%	100.0%	QFAPCTKLEKNFHIECTGCNSQSSSRASSISRNSSRSSSQCSRSGNSTRGTS PGSPSIGAVG
2 MN908947	94.7%	43.0%	QLPQCTTLKCFYAECSRGGSOASSRSSSRSGNSRNSTPCSSRGNSPARMA---GNGGDAF
3 KY417149	94.9%	42.6%	QLPQCTTLKCFYAECSRGGSOASSRSSSRSGNSRNSTPCSSRGNSPARMA---SGGGETZ
4 NC004718	94.9%	42.6%	QLPQCTTLKCFYAECSRGGSOASSRSSSRSGNSRNSTPCSSRGNSPARMA---SGGGETZ
5 AY278488	94.9%	42.6%	QLPQCTTLKCFYAECSRGGSOASSRSSSRSGNSRNSTPCSSRGNSPARMA---SGGGETZ
consensus/100%			Qhs.CTpLpKSFaheGotGssQuSSRuSShSRssSRsSo.CSppGsSstthu...ushGtsu
consensus/90%			Qhs.CTpLpKSFaheGotGssQuSSRuSShSRssSRsSo.CSppGsSstthu...ushGtsu
consensus/80%			QLPQCTTLKCFYAECSRGGSOASSRSSSRSGNSRNSTPCSSRGNSPARMA...SGGG-sZ
consensus/70%			QLPQCTTLKCFYAECSRGGSOASSRSSSRSGNSRNSTPCSSRGNSPARMA...SGGG-sZ

	cov	pid	241
1 NC019843	100.0%	100.0%	KVKQSOPKVIKKDAAAAKNKRHKRTSTKSFNMVQAFGRGPGDLCGNFGDLQNLKLCTEI
2 MN908947	94.7%	43.0%	KGQQQQGQTVTKKSAAEASKKPRKRTATKQYNVTOAFGRRGPEQTOCNFGDQDLIRQCTDY
3 KY417149	94.9%	42.6%	KGQQQQGQTVTKKSAAEASKKPRKRTATKQYNVTOAFGRRGPEQTOCNFGDQDLIRQCTDY
4 NC004718	94.9%	42.6%	KGQQQQGQTVTKKSAAEASKKPRKRTATKQYNVTOAFGRRGPEQTOCNFGDQDLIRQCTDY
5 AY278488	94.9%	42.6%	KGQQQQGQTVTKKSAAEASKKPRKRTATKQYNVTOAFGRRGPEQTOCNFGDQDLIRQCTDY
consensus/100%			KspQsQspslTKKSAAEappKRpKRTuTKtaNhsQAFGRGpTphQCNFGD.pL.+CT--
consensus/90%			KspQsQspslTKKSAAEappKRpKRTuTKtaNhsQAFGRGpTphQCNFGD.pL.+CT--
consensus/80%			KGQQQQGQTVTKKSAAEASKKPRKRTATKQYNVTOAFGRRGPEQTOCNFGDQ-LIRQCTDY
consensus/70%			KGQQQQGQTVTKKSAAEASKKPRKRTATKQYNVTOAFGRRGPEQTOCNFGDQ-LIRQCTDY

	cov	pid	321
1 NC019843	100.0%	100.0%	MSQFKLTHQNDDHGNPVYFLRYSGALKDDKNDNYNKKLELLEQNIDAYKTFEPKKEKKQK
2 MN908947	94.7%	43.0%	MSRIGMEVTP-----SGTWLTYHGAIKDDKDPQFKDNVILLNKHIDAYKTFEPTEPKKDI
3 KY417149	94.9%	42.6%	MSRIGMEVTP-----SGTWLTYHGAIKDDKDPQFKDNVILLNKHIDAYKTFEPTEPKKDI
4 NC004718	94.9%	42.6%	MSRIGMEVTP-----SGTWLTYHGAIKDDKDPQFKDNVILLNKHIDAYKTFEPTEPKKDI
5 AY278488	94.9%	42.6%	MSRIGMEVTP-----SGTWLTYHGAIKDDKDPQFKDNVILLNKHIDAYKTFEPTEPKKDI
consensus/100%			MSphtphps.....sshAlpypGALKDdsKsPpapc.l.LLpppIDAYKTFE.pE.kpct
consensus/90%			MSphtphps.....sshAlpypGALKDdsKsPpapc.l.LLpppIDAYKTFE.pE.kpct

MView 1.63, Copyright © 1997-2018 Nigel P. Brown